UNLIMITED TURBO SHORT - ELI LILLY & CO | Real-time Bid/Ask 02:41:07 27/06/2024 pm IST | ||
| 5.61 EUR / 5.76 EUR | -7.11% |
|
| Current month | -54.70% | ||
| 1 month | -56.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 5.76 | -5.88% |
| 26/24/26 | 6.12 | +3.20% |
| 25/24/25 | 5.93 | -11.49% |
| 24/24/24 | 6.7 | -10.90% |
| 21/24/21 | 7.52 | -2.97% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 01:05 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68PW |
| ISIN | DE000PC68PW8 |
| Date issued | 25/03/2024 |
| Strike | 962 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.59 € |
|---|---|
| Lowest since issue | 5.38 € |
| Spread | 0.15 € |
| Spread % | 2.60% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
